Open AccessUse of real-world evidence for oncology clinical decision making in emerging economies
Author(s) -
Fernando Petracci,
Chirag Ghai,
Andrew Pangilinan,
Luis Alberto Suarez,
Roberto Uehara,
Marwan Ghosn
Publication year - 2021
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2021-0425
Subject(s) - medicine , clinical trial , comparative effectiveness research , health care , randomized controlled trial , dosing , adverse effect , legislation , alternative medicine , economic growth , pharmacology , pathology , political science , law , economics
Real-world evidence (RWE) can provide insights into patient profiles, disease detection, treatment choice, dosing strategies, treatment sequencing, adverse event management and financial toxicity associated with oncology treatment. However, the full potential of RWE is untapped in emerging economies due to structural and behavioral factors. Structural barriers include lack of regulatory engagement, real-world data availability, quality and integrity. Behavioral barriers include entrenched healthcare professional behaviors that impede rapid RWE understanding and adoption. These barriers can be addressed with close collaboration of healthcare stakeholders; of whom, regulators need to be at the forefront given their ability to facilitate use of RWE in healthcare policy and legislation.